Table 5.
Species | Tumor | Model | Immunologic effect | References |
---|---|---|---|---|
Human | Breast carcinoma (n = 23) | HSP-70 (membrane)↑ | [122] | |
Breast carcinoma (n = 48) | CD3+, CD4+, CD8+ cells (tumor)↑ | [27] | ||
CD20+ cells (tumor)↑ | ||||
CD57+ cells (tumor)↑ | ||||
Pancreatic carcinoma (n = 15) | NK cells (blood)↑* | [123] | ||
Uveal melanoma (n = 5) | CD4+ cells (blood)↑ | [125] | ||
Osteosarcoma (n = 6) | CD4+ cells (blood)↑ | [126] | ||
HCC (n = 5) | ||||
RCC (n = 5) | ||||
| ||||
Mouse (Ajax) | Neuroblastoma | C1300 ± adriamycin | Tumor growth (rechallenge)↓ | [136] |
| ||||
Mouse (C57BL/6J) | HCC | H22 ± DC | Activation of CD8+ cells (spleen)↑ | [124] |
Tumor growth (rechallenge)↓ | ||||
H22 ± tumor lysate vaccine | Cytolytic activity (spleen)↑ | [121] | ||
Tumor growth (rechallenge)↓ |
*NK cell phenotype was not specified.